BioClinica, Inc. announced the launch of its new IVR/IWR (interactive voice response/interactive web response) platform, Trident IWR, at the 2010 Society for Clinical Data Management Annual Conference (SCDM). Trident IWR’s interface provides clinical operations personnel with an intuitive and faster way to directly set up, monitor, and maintain randomization and supplies for their clinical trials.
“We believe that Trident will fundamentally change the IVR/IWR market. Trident gives customers the ability to build complex trials in a quicker and less costly manner than previous alternatives which require the development of custom programming for each new clinical trial,” said Mark Weinstein, CEO of BioClinica.
Designed from inception as a web-based system, Trident simultaneously delivers IVR phone support through the same simplified configuration process. It is fully synchronized with BioClinica Optimizer a clinical supply simulation and visualization package. Study designs simulated in Optimizer can configure Trident IWR to precisely match the optimal scenario identified using Optimizer. After deployment, Trident data can update Optimizer, and then Optimizer can re-simulate and reforecast. BioClinica will conduct educational Trident-related webinars beginning in November 2010. For more information about these sessions please visit: http://www.bioclinica.com/webinars/.
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
Gilead Shares Final Data from Phase III MYR301 Trial of Bulevirtide in Chronic Hepatitis Delta Virus
May 7th 2025Long-term results from the study show 90% of patients with chronic HDV who achieved undetectable HDV RNA at 96 weeks of treatment remained undetectable for nearly 2 years post-treatment.